Navigation Links
Switzerland signs the ELIXIR consortium agreement and contributes €35 million
Date:10/30/2013

Switzerland's State Secretary for Education, Research and Innovation, Dr Mauro Dell'Ambrogio, has signed the ELIXIR Consortium Agreement for the establishment of ELIXIR, the European Life science Infrastructure for Biological Information. This brings closer the time when five Member States will have signed, and the Consortium Agreement will enter into force. The Swiss government has committed to investing 35 million over the four-year period from 2013 to 2016. This monetary contribution is mainly provided through financial support to SIB Swiss Institute of Bioinformatics the Swiss ELIXIR Node. However, the experience and expertise of SIB are also an important part of Switzerland's participation. Access to SIB's bioinformatics core resources and many other high-quality services, as well as the benefit of its solid experience in bioinformatics training will be major assets in the launch and success of ELIXIR.

The deluge of data produced by life science researchers thanks to new-generation technologies is a very positive development, given the wealth of information hidden in this data. Our society is constantly being challenged by crucial questions related to food, energy, the environment and, of course, health. Such data is a windfall for researchers provided that both the information and the bioinformatics resources for its analysis are accessible over the long term. ELIXIR is the European consortium, whose aim is to set up and operate a sustainable European infrastructure for biological information to support life science research and its translation to medicine, the environment, the bio-industries and society. This requires international coordination and the assurance of long-term funding.

The International Consortium Agreement signed by Switzerland today is key for the set-up of ELIXIR. Niklas Blomberg, Director of ELIXIR, is "very pleased that Switzerland, a pioneer and one of the world leaders in bioinformatics, is one of the first Member States to ratify the Agreement". Switzerland, which had already signed the Memorandum of Understanding in 2011, has thus confirmed its participation in the project. Research, life sciences and bioinformatics have been strongly supported by the Swiss government for many years, which is one of the reasons why Switzerland currently has a robust bioinformatics infrastructure.

SIB, the Swiss node of ELIXIR, is pleased to lend its support to ELIXIR

Since its inception, SIB, which is celebrating its 15th anniversary this year, has positioned itself as a major contributor to the life sciences. UniProtKB/Swiss-Prot, neXtProt, STRING, SWISS-MODEL are only a few of the core resources that have been created by SIB and are available to the life science research community worldwide. In total, more than 130 resources are accessible through SIB's web portal ExPASy (http://www.expasy.org). SIB, whose infrastructure and research groups are located in the major Swiss Universities and Federal Institutes of Technology, has a long experience in interinstitutional, intercantonal and international collaboration. Training the next generation of bioinformaticians is another of the Institute's roles, and demonstrates how SIB's missions are in tune with those of ELIXIR. According to Ron Appel, Executive Director of SIB, "ELIXIR will give a new dimension to European collaboration and open the door to the future of science".


'/>"/>

Contact: Irene Perovsek
irene.perovsek@isb-sib.ch
41-216-924-054
Swiss Institute of Bioinformatics
Source:Eurekalert

Related biology news :

1. Empa researchers join Quantis to open new branch in Switzerland
2. BioClaim, Inc. Signs Biometric Software Contract with Amerigroup Florida
3. Leopoldina signs cooperation agreement with the Academy of Science of South Africa
4. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
5. Light and nanoprobes detect early signs of infection
6. Encouraging signs for bee biodiversity
7. Early warning signs of population collapse
8. Shedding light on a gene mutation that causes signs of premature aging
9. Genetic signs of alcoholism in women studied for the first time
10. Streams show signs of degradation at earliest stages of urban development
11. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) ... nodule patient management. In addition to optimizing care coordination ... the lung, UCHealth looks to improve provider workflow by ... Stephanie Brown, RN , Thoracic Nurse Navigator, ... an Excel spreadsheet, which was extremely arduous and susceptible ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search ... Commercial Officer with GenePeeks. Matt is a veteran life sciences and molecular ... genomics company focused on identifying inherited disease risk in future generations. In his ...
(Date:2/15/2017)... 15, 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter and full year ended December ... year for Vanda as we continued to demonstrate ... long-term exclusivity for Fanapt," said Mihael H. Polymeropoulos, ... emerging pipeline with important 2017 milestones underscores Vanda,s ...
Breaking Biology Technology: